Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.751
+0.007 (0.90%)
Nov 6, 2024, 4:00 PM EST - Market closed
Equillium Revenue
Equillium had revenue of $13.85M in the quarter ending June 30, 2024, with 51.83% growth. This brings the company's revenue in the last twelve months to $42.62M, up 26.25% year-over-year. In the year 2023, Equillium had annual revenue of $36.08M with 128.97% growth.
Revenue (ttm)
$42.62M
Revenue Growth
+26.25%
P/S Ratio
0.61
Revenue / Employee
$968,705
Employees
44
Market Cap
26.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Burning Rock Biotech | 70.15M |
DarioHealth | 19.15M |
NeuroOne Medical Technologies | 3.92M |
Longeveron | 1.23M |
IGC Pharma | 1.06M |
EQ News
- 6 days ago - Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
- 4 weeks ago - Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
- 2 months ago - Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - Business Wire
- 2 months ago - Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference - Business Wire
- 3 months ago - Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights - Business Wire
- 3 months ago - Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease - Business Wire
- 3 months ago - Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance - Business Wire